These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36991096)

  • 1. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin.
    Shimazu Y; Kanda J; Kosugi S; Ito T; Kaneko H; Imada K; Shimura Y; Fuchida SI; Fukushima K; Tanaka H; Yoshihara S; Ohta K; Uoshima N; Yagi H; Shibayama H; Yamamura R; Tanaka Y; Uchiyama H; Onda Y; Adachi Y; Hanamoto H; Takahashi R; Matsuda M; Miyoshi T; Takakuwa T; Hino M; Hosen N; Nomura S; Shimazaki C; Matsumura I; Takaori-Kondo A; Kuroda J
    Sci Rep; 2023 Mar; 13(1):5159. PubMed ID: 36991096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocyte or white blood cell counts and β
    Shimazu Y; Kanda J; Kaneko H; Imada K; Yamamura R; Kosugi S; Shimura Y; Ito T; Fuchida SI; Uchiyama H; Fukushima K; Yoshihara S; Hanamoto H; Tanaka H; Uoshima N; Ohta K; Yagi H; Shibayama H; Onda Y; Tanaka Y; Adachi Y; Matsuda M; Iida M; Miyoshi T; Matsui T; Takahashi R; Takakuwa T; Hino M; Hosen N; Nomura S; Shimazaki C; Matsumura I; Takaori-Kondo A; Kuroda J;
    Ther Adv Hematol; 2022; 13():20406207221142487. PubMed ID: 36530751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
    Nakamura N; Arima N; Takakuwa T; Yoshioka S; Imada K; Fukushima K; Hotta M; Fuchida SI; Kanda J; Uoshima N; Shimura Y; Tanaka H; Ohta K; Kosugi S; Yagi H; Yoshihara S; Yamamura R; Adachi Y; Hanamoto H; Shibayama H; Hosen N; Ito T; Shimazaki C; Takaori-Kondo A; Kuroda J; Matsumura I; Hino M;
    Ann Hematol; 2024 Mar; ():. PubMed ID: 38492020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.
    Hoylman E; Brown A; Perissinotti AJ; Marini BL; Pianko M; Ye JC; Campagnaro E; Nachar VR
    Leuk Lymphoma; 2020 Mar; 61(3):691-698. PubMed ID: 31739729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.
    Gibiansky L; Passey C; Roy A; Bello A; Gupta M
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):243-57. PubMed ID: 26993283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once Monthly Elotuzumab and Lenalidomide Plus Dexamethasone for Multiple Myeloma: A Multicenter Observation Study.
    Suzuki K; Matsumoto M; Hiramatsu Y; Takezako N; Tamai Y; Suzuki K
    Acta Haematol; 2023; 146(2):125-136. PubMed ID: 36538896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
    N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.
    Danhof S; Strifler S; Hose D; Kortüm M; Bittrich M; Hefner J; Einsele H; Knop S; Schreder M
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):561-571. PubMed ID: 30519736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
    Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legieć W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špička I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;
    Lancet Haematol; 2022 Jun; 9(6):e403-e414. PubMed ID: 35550060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
    Usmani SZ; Hoering A; Ailawadhi S; Sexton R; Lipe B; Hita SF; Valent J; Rosenzweig M; Zonder JA; Dhodapkar M; Callander N; Zimmerman T; Voorhees PM; Durie B; Rajkumar SV; Richardson PG; Orlowski RZ;
    Lancet Haematol; 2021 Jan; 8(1):e45-e54. PubMed ID: 33357482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
    Lonial S; Dimopoulos M; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos MV; Magen H; Belch A; Reece D; Beksac M; Spencer A; Oakervee H; Orlowski RZ; Taniwaki M; Röllig C; Einsele H; Wu KL; Singhal A; San-Miguel J; Matsumoto M; Katz J; Bleickardt E; Poulart V; Anderson KC; Richardson P;
    N Engl J Med; 2015 Aug; 373(7):621-31. PubMed ID: 26035255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study.
    Atrash S; Thompson-Leduc P; Tai MH; Kaila S; Gray K; Ghelerter I; Lafeuille MH; Jayabalan D; Lefebvre P; Rossi A
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e708-e715. PubMed ID: 35490154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Based Determination of Elotuzumab Pharmacokinetics in Japanese Patients With Multiple Myeloma Incorporating Time-Varying M Protein.
    Ide T; Roy A; Imai Y; Vezina HE
    J Clin Pharmacol; 2021 Jan; 61(1):64-73. PubMed ID: 32656777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
    Laubach JP; Paba Prada CE; Richardson PG; Longo DL
    Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.